248282-01-1,MFCD18633277
Catalog No.:AA00BJKV

248282-01-1 | Paquinimod

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
97%
in stock  
$28.00   $19.00
- +
5mg
97%
in stock  
$69.00   $49.00
- +
10mg
97%
in stock  
$102.00   $72.00
- +
50mg
97%
in stock  
$287.00   $201.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA00BJKV
Chemical Name:
Paquinimod
CAS Number:
248282-01-1
Molecular Formula:
C21H22N2O3
Molecular Weight:
350.4110
MDL Number:
MFCD18633277
SMILES:
CCN(C(=O)c1c(O)c2c(CC)cccc2n(c1=O)C)c1ccccc1
Properties
Computed Properties
 
Complexity:
580  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0  
Defined Bond Stereocenter Count:
0  
Formal Charge:
0  
Heavy Atom Count:
26  
Hydrogen Bond Acceptor Count:
3  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0  
Rotatable Bond Count:
4  
Undefined Atom Stereocenter Count:
0  
Undefined Bond Stereocenter Count:
0  
XLogP3:
3.8  

Literature

Title: Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus.

Journal: Arthritis and rheumatism 20120501

Title: Specific effect of immunomodulatory quinoline-3-carboxamide ABR-215757 in GM-CSF stimulated bone marrow cell cultures: block of initiation of proliferation of Gr-1+ cells.

Journal: International immunopharmacology 20110801

Title: The impact of a new immunomodulator oxo-quinoline-3-carboxamide on the progression of experimental lupus.

Journal: International immunopharmacology 20041101

Title: Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.

Journal: Journal of medicinal chemistry 20040408

Title: Schelbergen RF, et al. Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Ann Rheum Dis. 2015 Dec;74(12):2254-8.

Title: Tahvili S, et al. Paquinimod prevents development of diabetes in the non-obese diabetic (NOD) mouse. PLoS One. 2018 May 9;13(5):e0196598.

Title: Qirui Guo, et al. Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19. Cell Host Microbe. 2021 Feb 10;29(2):222-235.e4.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:248282-01-1 Molecular Formula|248282-01-1 MDL|248282-01-1 SMILES|248282-01-1 Paquinimod
Catalog No.: AA00BJKV
248282-01-1,MFCD18633277
248282-01-1 | Paquinimod
Pack Size: 1mg
Purity: 97%
in stock
$28.00 $19.00
Pack Size: 5mg
Purity: 97%
in stock
$69.00 $49.00
Pack Size: 10mg
Purity: 97%
in stock
$102.00 $72.00
Pack Size: 50mg
Purity: 97%
in stock
$287.00 $201.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA00BJKV
Chemical Name: Paquinimod
CAS Number: 248282-01-1
Molecular Formula: C21H22N2O3
Molecular Weight: 350.4110
MDL Number: MFCD18633277
SMILES: CCN(C(=O)c1c(O)c2c(CC)cccc2n(c1=O)C)c1ccccc1
Properties
Complexity: 580  
Covalently-Bonded Unit Count: 1  
Defined Atom Stereocenter Count: 0  
Defined Bond Stereocenter Count: 0  
Formal Charge: 0  
Heavy Atom Count: 26  
Hydrogen Bond Acceptor Count: 3  
Hydrogen Bond Donor Count: 1  
Isotope Atom Count: 0  
Rotatable Bond Count: 4  
Undefined Atom Stereocenter Count: 0  
Undefined Bond Stereocenter Count: 0  
XLogP3: 3.8  
Literature fold

Title: Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus.

Journal: Arthritis and rheumatism20120501

Title: Specific effect of immunomodulatory quinoline-3-carboxamide ABR-215757 in GM-CSF stimulated bone marrow cell cultures: block of initiation of proliferation of Gr-1+ cells.

Journal: International immunopharmacology20110801

Title: The impact of a new immunomodulator oxo-quinoline-3-carboxamide on the progression of experimental lupus.

Journal: International immunopharmacology20041101

Title: Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.

Journal: Journal of medicinal chemistry20040408

Title: Schelbergen RF, et al. Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Ann Rheum Dis. 2015 Dec;74(12):2254-8.

Title: Tahvili S, et al. Paquinimod prevents development of diabetes in the non-obese diabetic (NOD) mouse. PLoS One. 2018 May 9;13(5):e0196598.

Title: Qirui Guo, et al. Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19. Cell Host Microbe. 2021 Feb 10;29(2):222-235.e4.

Building Blocks More >
218795-74-5
218795-74-5
N1-(tert-butyl)-2-(2,4-dihydroxybenzylidene)hydrazine-1-carbothioamide
AA00BJVF | MFCD00096693
26620-08-6
26620-08-6
Benzene,2-ethoxy-1,3-dimethyl-
AA00BL3Z | MFCD23099761
27983-08-0
27983-08-0
3-Bromomethyltricyclo[3.3.1.13,7]decane-1-carboxylic acid
AA00BNO6 | MFCD00167827
270929-28-7
270929-28-7
2,6-DICHLORO-N-CYCLOPROPYL-4-PYRIMIDINAMINE
AA00BPOT | MFCD11520486
217951-45-6
217951-45-6
6-Chloro-4,5-difluoro-3H-1,3-benzodiazole
AA00BSGY | MFCD18807697
214767-15-4
214767-15-4
4-Imidazolidinecarboxylicacid,2-oxo-,(4R)-(9CI)
AA00BUHA | MFCD00272205
303996-31-8
303996-31-8
Phenol, 4-[[5,7-bis(trifluoromethyl)-1,8-naphthyridin-2-yl]oxy]- (9CI)
AA00BX0G | MFCD00140191
405060-95-9
405060-95-9
Salubrinal
AA00BXB4 | MFCD00548612
36877-68-6
36877-68-6
1H-Imidazole, nitro-
AA00BXIB | MFCD00005185
3840-27-5
3840-27-5
2,5-Dimethoxybenzyl chloride
AA00BXOZ | MFCD00092195
Submit
© 2017 AA BLOCKS, INC. All rights reserved.